Bil­lion­aire Di­et­mar Hopp steers his se­cre­tive Covid-19 biotech play­er to Nas­daq fol­low­ing ma­jor pact with GSK

One of the most se­cre­tive biotech can­di­dates to lead the de­vel­op­ment of a new mR­NA vac­cine to fight Covid-19 just filed their IPO pa­pers for Nas­daq.

Cure­Vac, which has been slow to re­veal de­tails about its bid to de­vel­op a new Covid-19 vac­cine, out­lined a slate of al­liances — in­clud­ing the news that its $1.8 bil­lion deal with Eli Lil­ly is ka­put — with a host of glob­al play­ers in­volved in its bid to cut to the front of the pack in mR­NA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER